Metabolic Imaging Detects Low Levels of Glycolytic Activity That Vary with Levels of c-Myc Expression in Patient-Derived Xenograft Models of Glioblastoma.
American Association for Cancer Research
MetadataShow full item record
Mair, R., Wright, A. J., Ros, S., Hu, D., Booth, T., Kreis, F., Rao, J., et al. (2018). Metabolic Imaging Detects Low Levels of Glycolytic Activity That Vary with Levels of c-Myc Expression in Patient-Derived Xenograft Models of Glioblastoma.. Cancer research, 78 (18), 5408-5418. https://doi.org/10.1158/0008-5472.can-18-0759
13C magnetic resonance imaging (MRI) of hyperpolarized [1-13C]pyruvate metabolism has been used in oncology to detect disease, investigate disease progression, and monitor response to treatment with a view to guiding treatment in individual patients. This technique has translated to the clinic with initial studies in prostate cancer. Here we use the technique to investigate its potential uses in patients with glioblastoma (GB). We assessed the metabolism of hyperpolarized [1-13C]pyruvate in an orthotopically implanted cell line model (U87) of GB and in patient-derived tumors, where these were produced by orthotopic implantation of cells derived from different patients. Lactate labeling was higher in the U87 tumor when compared to patientderived tumors, which displayed inter-tumoral heterogeneity, reflecting the intra- and inter-tumoral heterogeneity in the patients' tumors from which they were derived. Labeling in some patient-derived tumors could be observed before their appearance in morphological images, while in other tumors it was not significantly greater than the surrounding brain. Increased lactate labeling in tumors correlated with c-Myc driven expression of hexokinase 2 (HK2), lactate dehydrogenase A (LDHA) and the monocarboxylate transporters (MCT) and was accompanied by increased radio-resistance. Since c-Myc expression correlates with glioma grade, this study demonstrates that imaging with hyperpolarized [1-13C]pyruvate could be used clinically with GB patients to determine disease prognosis, to detect early responses to drugs that modulate c-Myc expression and to select tumors, and regions of tumors, for increased radiotherapy dose.
Cell Line, Tumor, Animals, Humans, Rats, Rats, Nude, Glioblastoma, Brain Neoplasms, Disease Models, Animal, Doxycycline, Proto-Oncogene Proteins c-myc, RNA, Small Interfering, Magnetic Resonance Imaging, Prognosis, Magnetic Resonance Spectroscopy, Neoplasm Transplantation, Glycolysis, Female, Male, Exome, Heterografts
The work was supported by a Cancer Research UK Programme grant (17242) and by the CRUK-EPSRC Imaging Centre in Cambridge and Manchester (16465) awarded to K. M. Brindle. F. Kreis was supported by a Marie Curie ITN studentship (EUROPOL) and R. Mair by Addenbrooke's Charitable Trust and a CRUK Cambridge Centre Fellowship.
Cancer Research UK (CB4100)
Addenbrooke's Charitable Trust (ACT) (unknown)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (642773)
Cancer Research UK (16465)
Cancer Research UK (C48525/A18345)
MEDICAL RESEARCH COUNCIL (G1000265)
External DOI: https://doi.org/10.1158/0008-5472.can-18-0759
This record's URL: https://www.repository.cam.ac.uk/handle/1810/283018